emerging landscape of oncogenic signatures across human cancers

17
Raunak Shrestha PhD Student (Bioinformatics) Dr. Colin Collin’s Lab 31 st October 2013

Upload: raunak-shrestha

Post on 31-May-2015

205 views

Category:

Health & Medicine


0 download

DESCRIPTION

Emerging landscape of oncogenic signatures across human cancers

TRANSCRIPT

Page 1: Emerging landscape of oncogenic signatures across human cancers

Raunak ShresthaPhD Student (Bioinformatics)

Dr. Colin Collin’s Lab31st October 2013

Page 2: Emerging landscape of oncogenic signatures across human cancers

2

Page 3: Emerging landscape of oncogenic signatures across human cancers

3

The Cancer Genome Atlas Pan-Cancer analysis project

Ashworth & Hudson. Nature 502, 306–307 (17 October 2013)

Page 4: Emerging landscape of oncogenic signatures across human cancers

4

Two fundamental observations across various cancer types

• tumors originating in the same organ or tissue vary substantially in genomic alterations

• similar patterns of genomic alteration are observed in tumors from different tissues of origin

Page 5: Emerging landscape of oncogenic signatures across human cancers

5

In brief• Analyzed >3000 tumors across 12 different cancer types• integrated multiple types of alterations (genomic & epigenomic)• Used hierarchical stratification approach to obtain clusters of

tumors• Observed two major clusters of tumors

– Cluster I: primarily with somatic mutation (M class)– Cluster II: primarily with copy number alterations (C class)

• Observed a striking inverse relationship between # of copy number alterations & # of somatic mutations (when averaged over 12 cancer types)

• Oncogenic signatures were used to derive the oncogenic pathways

• Nominated therapeutically actionable targets across tumor types

Page 6: Emerging landscape of oncogenic signatures across human cancers

6

3299 tumors from 12 cancer types 3299 tumors

Recurrentevents

Selected Functional

Events (SFE)

116 Gains151 Losses199 Mutations13 Meth

Somatic Mutations

Copy Number Alterations

DNA Methylation events

Geneexpression

Page 7: Emerging landscape of oncogenic signatures across human cancers

7

Page 8: Emerging landscape of oncogenic signatures across human cancers

8

Hierarchical ClassificationM Class (primarily with mutations)

C Class (primarily with copy number alterations)

Page 9: Emerging landscape of oncogenic signatures across human cancers

9

Cancer Genome Hyperbola

inverse relationship between # of copy number alterations & # of somatic mutations (when averaged over 12 cancer types)

Page 10: Emerging landscape of oncogenic signatures across human cancers

10

Cancer Genome Hyperbola

Page 11: Emerging landscape of oncogenic signatures across human cancers

11

ARID1A is a member of the chromatin-remodeling complex SWI/SNF and, although truncating mutations in this gene have been reported in several tumor types, no recurrent hotspot had previously been identified.

CTCF encodes a chromatin-binding factor that acts as both a repressor and an activator of multiple genes, including known oncogenes and tumor suppressor genes (MYC, PLK, PIM1, CDKN2A and IGF2)

Page 12: Emerging landscape of oncogenic signatures across human cancers

12

Page 13: Emerging landscape of oncogenic signatures across human cancers

13

From Oncogenesis to Therapy

Page 14: Emerging landscape of oncogenic signatures across human cancers

14

From Oncogenesis to Therapy

Page 15: Emerging landscape of oncogenic signatures across human cancers

15

Page 16: Emerging landscape of oncogenic signatures across human cancers

16

Summary

• Tissue-independent classification of tumors on the basis of genetic and epigenetic alterations;– Thousands of molecular alterations to a few hundred plausibly

functional events.– Stratify tumors on the basis of distinct patterns of those

selected alteration events.

• Hierarchical classification identified M class and C class of tumors, and their subclasses

• Provide insight into the mechanisms of oncogenesis and therapeutically actionable alterations

Page 17: Emerging landscape of oncogenic signatures across human cancers

17